Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Turn Therapeutics Inc. Common Stock

TTRX

Turn Therapeutics Inc is a clinical-stage biotechnology and medical device development company built around its proprietary platform technology called PermaFusion designed to enhance drug performance. The company is developing non-systemic, non-biologic topical immunomodulators for inflammatory skin disease. Its program, GX-03, is being studied for moderate-to-severe eczema based on preclinical evidence of cytokine inhibition and reduced eczema severity, as well as a favorable real-world tolerability record from prior cleared medical device indications for the same formula. GX-03 is currently being evaluated in an ongoing, randomized, double-blind, vehicle-controlled clinical study designed to assess its potential as a topical treatment for moderate-to-severe eczema.

Last trade $8.15
Day change -$0.40 (-4.68%)
Day range $8.10 – $9.03
Volume 95,133
Market cap $261M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$261.4M
Price / earnings
—
Price / book
45.92×
Price / sales
—
EV / sales
—
EV / EBITDA
-36.77×

Profitability

Earnings per share
-$0.42
Return on assets
-78.12%
Return on equity
-224.39%
Dividend yield
0%

Liquidity and leverage

Debt / equity
1.09×
Current ratio
3.19×
Quick ratio
3.19×
Cash ratio
2.98×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$5.28M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for TTRX, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025
Revenue$0$0$0$0
Cost of revenue$0$0$0$0
Gross profit$0$0$0$0
Selling, general and administrative$1.38M$1.15M$1.14M$2.16M
Research and development$605.2K$475.06K$109.43K$34.93K
Total operating expenses$1.98M$1.63M$1.25M$2.19M
Operating income-$1.98M-$1.63M-$1.25M-$2.19M
Interest expense-$341.21K-$241.36K$0$0
Income before taxes-$6.23M-$5.85M-$970.97K$279.07K
Income taxes$0$0$0$0
Net income-$6.23M-$5.85M-$970.97K$279.07K
Net income attributable to common shareholders-$6.23M-$5.85M-$970.97K$279.07K
EBITDA-$1.94M-$1.64M-$1.23M-$2.18M
Basic earnings per share-$0.21-$0.20-$0.03$0.01
Diluted earnings per share-$0.21-$0.20-$0.03$0.01

Recent news

Company coverage with links to the original publishers.

Publication times in UTC

No recent company news found.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.